Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: IVD Triage

This article was originally published in The Gray Sheet

Executive Summary

IVD Triage: Additions to FDA's Tier I category of in vitro diagnostics scheduled to take effect June 1, according to FDA's Division of Clinical Laboratory Devices. The agency says that as a result of the triage process, the number of Tier I IVDs, which receive a simplified, administrative review, has been increased by 20% in the Clinical Chemistry Branch, 20% in the Microbiology Branch, and 14% in the Immunology Branch. There is no change in the number of Tier I IVDs in the Hematology Branch. FDA gathered input from the public, industry and healthcare professionals on its triage process at an Oct. 30 workshop in Rockville, Maryland ("The Gray Sheet" Nov. 6, 1995, p. 8)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT005972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel